To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

Although myocarditis and pericarditis were not observed as adverse events in coronavirus
disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected …

The American College of Cardiology (ACC) has a long history of develo** documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Importance Vaccination against COVID-19 provides clear public health benefits, but
vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID …

Viral infections are a leading cause of myocarditis and pericarditis worldwide, conditions that
frequently coexist. Myocarditis and pericarditis were some of the early comorbidities …

Recent advances in mRNA technology and its delivery have enabled mRNA-based
therapeutics to enter a new era in medicine. The rapid, potent, and transient nature of mRNA …

Background Reports have suggested an association between the development of
myocarditis and the receipt of messenger RNA (mRNA) vaccines against coronavirus …

Abstract Background Approximately 5.1 million Israelis had been fully immunized against
coronavirus disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger …